# Dunleavy_2022_Inflammation in first-episode psychosis The contribution of inflammatory biomarkers to the emergence of negative symptoms, a systematic review and meta-analysis.

Received: 22 November 2021 

DOI: 10.1111/acps.13416  

|  Accepted: 13 February 2022

S Y S T E M A T I C   R E V I E W

Inflammation in first- episode psychosis: The contribution 
of inflammatory biomarkers to the emergence of negative 
symptoms, a systematic review and meta- analysis

Connor Dunleavy1,2
Stephen J. Wood1,2,4,5  |   Sarah Aldred1

  |   Richard J. Elsworthy1  |   Rachel Upthegrove2,3  |    

1School of Sport, Exercise, and 
Rehabilitation Sciences, University of 
Birmingham, Birmingham, UK
2School of Psychology, Institute 
for Mental Health, University of 
Birmingham, Birmingham, UK
3Early Intervention Service, 
Birmingham Women's and 
Children's NHS Foundation Trust, 
Centre for Human Brain Health 
(CHBH), University of Birmingham, 
Birmingham, UK
4Centre for Youth Mental Health, 
University of Melbourne, Melbourne, 
Victoria, Australia
5Orygen Youth Health, Parkville, 
Victoria, Australia

Correspondence
Connor Dunleavy and Sarah Aldred, 
School of Sport, Exercise, and 
Rehabilitation Sciences, University of 
Birmingham, Birmingham B15 2TT, 
UK.
Emails: s.aldred.1@bham.ac.uk; 
cxd680@student.bham.ac.uk

Funding information
This research did not receive any 
specific grant from funding agencies in 
the public, commercial, or not- for- profit 
sectors.

Abstract
Objective:  To  provide  a  comprehensive  analysis  of  cytokine  perturbations  in 
antipsychotic- naïve first- episode psychosis (FEP) populations and assess the rela-

tionship between inflammatory biomarkers and negative symptom severity.
Methods: A systematic review and meta- analysis following PRISMA guidelines 
were conducted. A total of 1042 records were identified via systematic search of 

EMBASE, MEDLINE and APA PsycInfo databases. Sixteen studies met the inclu-

sion  criteria  and  were  eligible  for  inclusion  in  the  review.  Ten  of  these  studies 

had sufficient data for inclusion in a random effects, pooled- effect meta- analysis.
Results: A significant and large effect size was reported for IFN- γ, IL- 6 and IL- 12, 
and a moderate effect size reported for IL- 17 (p = <0.05) in people with antipsy-
chotic naive first episode psychosis, compared to healthy controls, suggesting a 

significant elevation in proinflammatory cytokine concentration. Non- significant 
effect sizes were reported for TNF- α, IL- 1β, IL- 2, IL- 4, IL- 8 and IL- 10 (p = >0.05). 
Regarding proinflammatory cytokines and relationships to negative symptomol-

ogy,  moderate  positive  relationships  were  reported  for  negative  symptoms  and 
IL- 1β, IL- 2, IL- 6 and TNF- α, across four studies. For anti- inflammatory cytokines, 
one  strong  and  one  weak- to- moderate  negative  relationship  was  described  for 

IL- 10 and negative symptoms. Contrastingly, a strong positive relationship was 

reported for IL- 4 and negative symptoms.
Conclusion:  There  is  evidence  of  significantly  elevated  proinflammatory  cy-
tokines  in  antipsychotic- naïve  FEP  populations,  alongside  promising  findings 

from cohort data suggesting an interaction between inflammation and primary 

negative symptomology. Future studies should seek to come to a consensus on 

a panel of cytokines that relate most specifically to negative symptoms, and con-

sider longitudinal studies to investigate how cytokine fluctuations may relate to 

exacerbation of symptoms.

This is an open access article under the terms of the Creative Commons Attribution- NonCommercial- NoDerivs License, which permits use and distribution in any 
medium, provided the original work is properly cited, the use is non- commercial and no modifications or adaptations are made.
© 2022 The Authors. Acta Psychiatrica Scandinavica published by John Wiley & Sons Ltd.

6  | 

wileyonlinelibrary.com/journal/acps

Acta Psychiatr Scand. 2022;146:6–20.

  
  
K E Y W O R D S

cytokines, immune response, inflammation, negative symptoms, schizophrenia

| 7

1 

|  INTRODU CT ION

Schizophrenia (SCZ) is a highly debilitating mental illness 
that affects over 20 million individuals globally, associated 
with a reduced quality of life, severe cognitive dysfunction 
and substantially increased mortality rates.1,2 SCZ is widely 
recognised  as  a  neurodevelopmental  disorder  that  often 
becomes apparent at a critical period in early adulthood.3 
Through the interaction of genetic predisposition and en-
vironmental  stressors,  an  individual  may  be  particularly 
vulnerable to developing SCZ.4 Typically, risk factors for 
SCZ can trigger a first episode of psychosis (FEP), which 
is an acute period whereby an individual begins to experi-
ence some  loss of  contact with reality. This  may include 
sporadic hallucinations, delusions, disturbances in behav-
iour, thought processes and functioning.5 Following treat-
ment, most individuals may initially achieve remission of 
symptoms. However, for approximately one in three, per-
sistence and relapse of symptoms occur and this increases 
the risk of transition to more persistent SCZ pathology.6

A  common  feature  associated  with  FEP  is  the  emer-
gence  of  negative  symptoms.  Negative  symptomology  is 
associated with a significantly reduced quality of life and 
social functioning,7,8 and is classically described as a ‘loss 
of  function’.  This  includes  two  subdomains  concerned 
with  ‘diminished  expression’  and  ‘avolition- amotivation’. 
The  former  involves  the  absence  of  drive,  interest  and 
deficits  in  affective  responses.9  The  second  subdomain, 
‘avolition- amotivation’,  are  symptoms  that  manifest  as 
asociality  and  specifically  motivational  anhedonia.10,11 
Negative  symptoms  can  be  further  defined  as  primary 
negative symptoms which are intrinsic to disease pathol-
ogy, or secondary negative symptoms which may present 
as  a  side- effect  of  other  conditions  such  as  comorbidity, 
concomitant  psychotic  symptoms,  or  medication  sta-
tus.12 Primary negative symptoms can emerge at any time 
throughout the duration of disease, display poor response 
trajectory to treatment,13 and have been suggested as pres-
ent in approximately 26% of FEP cohorts.14 However, this 
figure may vary dependent upon subdomains and specific 
items assessed, as well as control of confounding factors.14 
The  role  of  antipsychotic  medication  in  the  generation 
of negative symptoms remains controversial, as research 
suggests that antipsychotic drugs can cause presentation 
of sedatory, akinetic and amotivational behaviours which 
may  be  interpreted  as  a  negative  symptom,  making  pri-
mary  symptoms  increasingly  difficult  to  identify  and 
estimate.12,15,16  Furthermore,  It  is  well  established  that 
antipsychotic  medication  possesses  the  capacity  to  alter 

Summations

•  Proinflammatory  cytokines  are  significantly 
elevated  in  drug  naïve  first- episode  psychosis 
populations,  display  subtle  relationships  with 
primary negative symptom severity.

•  Inflammatory cytokines may represent a panel 
of biomarkers that could be used to stratify pa-
tients into subgroups experiencing primary neg-
ative  symptoms  or  deficit  schizophrenia,  who 
may benefit from anti- inflammatory treatment.

Limitations

•  Future research should seek to acknowledge a 
common method for cytokine quantification to 
allow  more  accurate  cross- study  comparisons 
and  consider  immune  cell  phenotyping  tech-
niques to further elucidate the ‘immune profile’ 
in psychosis.

•  Forthcoming  studies  should  also  consider  cy-
tokine  measurement  over  time  and  correlate 
cytokine  changes/exacerbations  with  specific 
primary negative symptoms, in order to estab-
lish a causal relationship between the two and 
differentiate  from  secondary  negative  symp-
toms and depression.

biomarkers that are perturbed in FEP and may be impli-
cated with the pathophysiology of primary negative symp-
toms,  therefore  medication  status  must  be  considered 
when investigating negative symptomology.15,17

Contemporary  evidence  suggests  a  link  between  per-
turbed  inflammatory  processes  and  negative  symptoms 
in FEP, and points to immune cell dysfunction within the 
brain and more globally in peripheral tissues. An exacer-
bated inflammatory cascade characterised by increased in 
immune activation, proinflammatory cytokine production 
and  oxidative  distress  is  present  in  both  FEP  and  estab-
lished SCZ, and may be a key mediator underlying negative 
symptom presentation.17– 19 It is suggested that peripheral 
immune responses are representative of the neuroimmune 
status of the brain, therefore systemic cytokine concentra-
tions are increasingly relevant for revealing how inflamma-
tion may confer specific symptom profiles in FEP. Multiple 
studies  have  suggested  relationships  between  peripheral 
inflammatory biomarkers and the emergence of negative 
symptoms  in  particular,  with  dysregulation  of  immune 

DUNLEAVY et al. 
   
8 

| 

cells and aberrations in proinflammatory cytokines noted 
as important.15,20– 23 The interaction between dysfunctional 
cytokine secretion and oxidative stress can result in tissue 
damage  and  neurodegeneration  that  may  contribute  to 
SCZ  pathology,  through  the  impairment  of  downstream 
signalling pathways including serotonergic, dopaminergic 
and  glutamatergic  neurotransmission,  ultimately  leading 
to the presentation of negative symptomology.15

Balance between the peripheral Th1, and Th2 inflam-
matory responses and overall cytokine production is cru-
cial for an efficient and regulated immune response, and 
perturbation of this balance can result in chronic inflam-
mation  and  deterioration  into  disease  (see  Figure  1).24 
Previous research supports the notion that proinflamma-
tory cytokines in the peripheral body systems are elevated 
in FEP and SCZ.15,17,25,26 However, evidence of a direct link 
between  inflammation  and  the  emergence  of  specifically 
negative symptoms is mixed, which may be due to small 
sample  sizes,  heterogeneity  in  illness  duration,  method-
ological  variations  in  cytokine  quantification  and  man-
agement of confounding factors.27 For example Zhu et al. 
(2018)28 reported significantly elevated plasma TNF- α con-
centrations  that  were  positively  correlated  with  negative 
symptomology  in  a  chronic  SCZ  cohort,  however,  these 
findings were not replicated in a drug- naive FEP popula-
tion. Elsewhere, however, correlations between TNF- α and 

negative symptoms have been identified across CHR,21 first 
episode29 and chronic medicated SCZ cohorts.23

In  order  to  most  accurately  identify  the  relationship 
between cytokines and negative symptoms, the current re-
view utilises a specific FEP definition that includes an es-
tablished F20 diagnosis status via a validated clinical tool 
(DSM- 5,  ICD- 10,  etc.),  absolute  medication  naivety  and 
less than 5 years of total illness duration. Using these crite-
ria enable a greater understanding of pathogenic processes 
that underlie the presentation of negative symptomology 
in FEP, where disease pathology is still in its infancy and 
unconfounded by chronicity of disease or side effects of an-
tipsychotic medication, both of which are known to influ-
ence cytokine concentration. This could enable the future 
stratification of patients experiencing negative symptoms, 
which may be critical in determining more effective thera-
peutic treatments for negative symptoms specifically.

1.1 

|  Aims of the study

The aim of this systematic review was to provide a com-
prehensive overview of cytokine perturbations in antipsy-
chotic naïve FEP populations and assess the relationship 
between  inflammatory  markers  and  negative  symptom 
severity.

F I G U R E   1  Under physiological conditions, the immune system protects the body from invading pathogens or damaged tissues 
through a highly regulated process, divided into generalised ‘innate’ response to infection, and specialised ‘adaptive’ defence associated 
with antibody production and memory function. Cytokines including TNF- α, IL- 1, IL- 6 and IL- 8 constitute the initial exacerbation of 
inflammation against pathogens. IFN- γ and IL- 12 promote further inflammation to kill intracellular parasites, constituting the T- Helper 1 
immune response. IL- 4, IL- 5 and IL- 13 function to compensate and extinguish neuroinflammation via anti- inflammatory action, termed the 
T- Helper 2 immune response. IL- 17 and IL- 23 further exacerbate the inflammatory state as part of the T- Helper 17 response. Finally, IL- 10 
and TGF- β dampen the inflammatory response of the aforementioned cytokines and represent the T- Regulatory response. APC, Antigen 
Presenting Cell; IFN, interferon; IL, Interleukin; TGF, Transforming Growth Factor; TNF, Tumour Necrosis Factor

DUNLEAVY et al. 
 
2 

|  MATERIALS A ND M ET HODS

2.1 

|  Study selection

Studies were systematically searched on the 1st September 
2021  via  the  Ovid  database  system,  using  Medline, 
EMBASE  and  PsycInfo  databases,  in  accordance  with 
the  PRISMA  guidelines  to  ensure  high- quality  reporting 
of systematic reviews.30 The search was conducted using 
keywords  which  were  adjusted  appropriately  to  subject 
headings/MeSH  headings  dependent  on  the  database 
being  searched,  with  the  Ovid  ‘explode’  function  imple-
mented where appropriate. Keywords that were mapped 
to subject headings were also separately searched as a key-
word in order to collect all potentially relevant studies and 
negate any human error regarding database study input or 
keyword mapping, as advised by a library technician. An 
asterisk ‘*’ marks a truncated keyword where any alterna-
tive ending of a word is retrieved.

The key word search terms included were as follows: 
(“schizo*” OR “psychosis” OR “psychoses” OR “first ep-
isode”  OR  “first  episode  psychosis”  OR  “first  psychotic 
episode”  OR  “FEP”  OR  “psychotic  disorder”  OR  “early 
onset” OR “early intervention” OR “drug naïve” OR “med-
ication naïve”) AND (“inflammat*” OR “cytokin* OR “in-
terleukin*” OR “tumour necrosis factor” OR “TNF- alpha” 
OR  “interferon”  OR  “immune  response”  OR  “immune 
dysregulation” OR “cytokine production) AND (negative 
symptom* OR “negative syndrome” OR “alogia” OR “an-
ergia” OR “anhedonia” OR “avolition” OR “apathy” OR 
“asociality” OR “affective flattening” OR “blunted affect” 
OR “diminished expression” OR “social withdrawal” OR 
“lossADJ1interest” OR “lackADJ1interest” OR “lossAD-
Jmotivat* OR “lackADJ1motivat*”).

Additional  limits  were  also  implemented  into  each 
search,  limited  to  (1)  human- based  studies,  (2)  exclude 
conference abstracts, (3) search limits from 1982 to 2021, 
in  line  with  the  implementation  of  the  Scale  for  the 
Assessment of Negative Symptoms (SANS) questionnaire 
(1982)  and  the  Positive  and  Negative  Syndrome  Scale 
(PANSS)  questionnaire  (1987),  widely  recognised  as  the 
‘gold- standard’  for  quantitative  assessment  of  negative 
symptoms.9,31  Studies  were  then  retained  or  discarded 
based on an agreed inclusion/exclusion criterion.

2.1.1 

|  Inclusion criteria

1.  Published  between  1982  and  2021
2.  Patients with an established diagnosis of FEP
3.  Within first 5 years of duration of illness (explicit meas-
urement  in  years,  or  deemed  within  criteria  based  on 
text information, as assessed by author)

| 9

4.  Antipsychotic  naïve  (or  a  subset  with  fully  stratified 

data for medication naïve FEP)

5.  Assessed  peripheral  circulating  cytokines  (via  blood, 

serum, plasma)

6.  Assessed negative symptoms
7.  Apparently healthy control group
8.  Human- based only

2.1.2 

|  Exclusion criteria

1.  In  vitro  studies
2.  Genetic studies
3.  Animal- based studies
4.  Review articles, Posters, Conference Abstracts
5.  Studies  not  measuring  peripheral  proinflammatory 

cytokines

6.  Studies not measuring negative symptoms
7.  Full text not available
8.  Not written in English

2.2 

|  Data extraction and analysis

Information  was  extracted  by  two  authors  (C.  Dunleavy 
&  S.  Aldred)  from  each  study  for  a  ‘three- phase  exclu-
sion’  process  of  studies  for  full  review.  In  phase  one 
(Identification),  any  duplicates,  posters  and  conference 
abstracts were excluded. Phase two (Screening) comprised 
the exclusion of records based on the title and/or abstract, 
in  accordance  with  the  agreed  inclusion/exclusion  crite-
rion.  In  phase  three  (Eligibility),  articles  were  assessed 
at  the  full- text  level,  in  which  population  demographic 
data,  duration  of  illness,  study  type,  medication  status, 
cytokine  concentration,  symptom  scale  measurement 
and outcome measures were extracted in order to deter-
mine eligibility in the systematic review, see Figure 2. If 
specific  data  required  to  determine  inclusion/exclusion 
were not available in the online version of a study, an at-
tempt was made to contact the author for supplementary 
data.  If  sufficient  data  were  still  not  available,  the  study 
was  excluded.  Studies  were  also  examined  for  overlap-
ping/duplicate  samples  or  measurements  and  excluded 
accordingly.  Mean,  standard  deviation  and  sample  size 
data  were  extracted  separately  from  each  study  for  each 
proinflammatory  cytokine  assessed,  for  both  FEP  and 
control groups, and converted to picograms per millilitre 
(pg/ml)  where  necessary.  Some  studies  divided  the  FEP 
group into sub- groups based on certain characteristics of 
interest,  therefore  in  order  to  combine  mean,  standard 
deviation and sample size of the relevant subgroups into 
one  homogenous  FEP  group,  the  formulas  proposed  by 
Cochrane Reviews were implemented.32

DUNLEAVY et al. 
   
10 

| 

F I G U R E   2  A flow chart displaying 
the selection process of studies included 
in the systematic review and meta- 
analysis

Mean  and  standard  deviation  values  were  also  ex-
tracted  for  the  negative  symptom  measurements  for  the 
patient groups only. Where appropriate, values presented 
in a format other than PANSS scale were converted into 
PANSS  Negative  values  based  on  a  formula  proposed  by 
Van Erp et al. (2014), to allow for comparison of the values 
across a normalised scale.

SANS— PANSS negative conversion equation
PANSS Negative = 7.1196 +(0.3362×SANS [composite] 

Total score).33

2.3 

|  Data analysis

Mean,  standard  deviation  and  sample  size  for  each  cy-
tokine assessed in two or more studies were entered into 
Revman  5.0  for  subsequent  analysis.  A  ‘random  effects’ 
model was selected as this statistical methodology consid-
ers heterogeneity that may be present between studies, as 
well  as  the  variance  in  potential  study  effect  during  the 
prediction  of  overall  effect  size.34  The  ‘inverse  variance’ 
method  was  implemented  to  assign  specific  weighting 

to  each  study  based  on  the  variance  of  the  effect,  there-
fore  more  comprehensive  studies  with  smaller  standard 
error  account  for  higher  overall  weights.  This  was  done 
in attempt to lessen error or inaccuracy of the overall ef-
fect size in meta- analysis.32 Individual standardised mean 
difference  (SMD)  was  calculated  for  each  cytokine  from 
each study included in meta- analysis with 95% confidence 
intervals, in addition to an overall effect size for cytokine 
concentration favouring an increase in FEP or control (dis-
played by Z score) with overall 95% confidence intervals, 
and significance values noted (p < 0.05). SMD calculation 
was implemented due to the expectance of high study het-
erogeneity,  and  potential  differences  in  sensitivity  of  cy-
tokine measurements. This minimised the methodological 
differences  between  studies,  and  provide  a  standardised 
result on a uniform scale based on the variability within 
a given study.35 Meta- regression analyses were performed 
to  assess  the  contribution  of  various  socioeconomic  and 
clinical factors that may further perturb cytokine concen-
trations  in  FEP.  Mean,  standard  deviation  and  sample 
size for each cytokine were inputted into Comprehensive 
Meta- Analysis  (CMA)  3.0  software  and  SMD  calculated. 

DUNLEAVY et al. 
 
Numerical values for potential confounding factors were 
then  extracted  from  papers,  converted  to  relevant  units 
and inputted into CMA for meta- regression analysis.

Inter- study  heterogeneity  was  evaluated  by  the  Tau² 
and  Chi- square  tests.  These  tests  determine  if  statistical 
heterogeneity  is  present  between  all  studies  for  a  given 
cytokine to determine if the change in cytokine concen-
tration  is  similar  across  papers.  The  I²  statistic  was  also 
calculated in order to display the percentage of variability 
in cytokine change across studies that is due to heteroge-
neity, which gives the reader an indication of the propor-
tion of variance between studies. Data from RevMan 5.0 
were displayed graphically via forest plots, with p < 0.05 
denoting  a  significant  effect  of  the  diagnosis  of  FEP  on 
cytokine concentration, when compared to an apparently 
healthy control population. In order to assess the poten-
tial relationship between cytokine concentration and FEP 
symptomology, mean, standard deviation and sample size 
for cytokine concentration and PANSS Negative from each 
study  included  in  the  meta- analysis,  was  entered  into 
GraphPad Prism 8.0 for subsequent regression analysis.

3 

|  RESULT S

Following  PRISMA  guidelines,  a  primary  systematic 
search  identified  1500  studies.  After  the  removal  of  458 
duplicate  records,  1042  studies  were  retrieved,  and  the 
title  and  abstracts  screened  against  the  identified  inclu-
sion  criteria.  Subsequently,  958  records  were  excluded. 
Full- text  analysis  was  then  undertaken  on  the  remain-
ing  84  records.  Articles  were  then  excluded  as  follows: 
Condition not classified as FEP (n = 15), negative symp-
toms not used as a main outcome measure (n = 14), partic-
ipants were not drug naïve (n = 12), study didn't measure/
report peripheral cytokines (n = 9), no apparently healthy 
control  group  (n  =  5),  not  in  English  language  (n  =  5), 
poster abstract only (n = 2), review article (n = 2). Finally, 
six  studies  were  excluded  due  to  duplication  of  the  par-
ticipant  sample  with  another  identified  paper  already 
included in this review.36– 41 Where duplicate participant 
samples were identified, the paper that was included was 
selected based upon (1) largest panel of cytokines assessed 
and (2) largest sample size respectively. The study selec-
tion process is displayed in Figure 2.

Data reviewed herein are included from FEP patients 
only,  as  identified  by  the  prespecified  inclusion  criteria. 
Where studies included data for participants in other dis-
ease groups (e.g. clinical high risk, chronic SCZ, depres-
sion),  only  data  on  participants  with  FEP  and  healthy 
controls  were  extracted.  Altogether,  16  studies  met  the 
inclusion  criteria  for  the  current  systematic  review  (see 
Table  1).  Within  the  16  included  studies,  the  data  from 

|  11

four  studies  were  not  provided  in  sufficient  detail  to  be 
included in meta- analysis. The authors of these four stud-
ies  were  contacted  and  additional  data  were  requested, 
but  not  received.  These  studies  were  therefore  included 
in the narrative section of the review only. Rationale for 
exclusion  from  meta- analysis  were  as  follows:  standard 
deviation not given for cytokine values (n = 2), Over 50% 
cytokines  at  or  below  limit  of  detection  (n  =  1),  actual 
cytokine values not given (n = 1). Furthermore, an addi-
tional two studies measured cytokines that were only fea-
tured  once  (IL- 3,  IL- 18),  therefore  were  not  assessed  via 
meta- analysis (n = 2).

3.1 

|  Meta- analysis

Ten  studies  met  the  inclusion  criteria  and  were  there-
fore  included  in  the  meta- analysis  to  assess  cytokine 
concentrations  in  FEP,  where  cytokines  were  measured 
across  two  or  more  studies.28,29,42– 49  Data  from  the  10 
included  studies  provided  information  on  651  antipsy-
chotic naïve FEP patients. The mean age of FEP patients 
was 25.18 ± 4.09 years, ranging from 14.7 to 29.07 years. 
From  the  same  ten  studies,  data  were  extracted  for  521 
apparently  healthy  control  subjects,  with  a  mean  age  of 
26.01 ± 4.78 years, ranging from 14.5 to 32.9 years.

Twenty- four different cytokines were assessed periph-
erally via ELISA, or similar assay. The following cytokines 
were assessed in more than one study: TNF- α, IFN- γ, IL- 
1β, IL- 2, IL- 6, IL- 8, IL- 12, IL- 17, (proinflammatory), IL- 4 
and  IL- 10  (anti- inflammatory).  The  data  for  each  cyto-
kine were included in a random- effects, pooled effect size 
model to determine which cytokines are significantly al-
tered in FEP. After transformation into SMD to avoid po-
tential  differences  in  ELISA  sensitivity,  a  random- effect, 
pooled- effect analysis suggested that four cytokines were 
significantly  upregulated  in  the  FEP  population,  when 
compared with control.

A significant effect size was reported for IFN- γ (4 stud-
ies, 168 patients, SMD = 1.22, 95% CI 0.14 to 2.31, Z = 2.21, 
I² = 94%), IL- 6 (5 studies, 251 patients, SMD = 1.38, 95% 
CI 0.54 to 2.22, Z = 3.21, I² = 94%), IL- 12 (2 studies, 87 pa-
tients, SMD 3.43, 95% CI 2.12 to 4.73, Z = 5.15, I² = 80%) 
and  IL- 17  (3  studies,  130  patients,  SMD  =  0.72,  95%  CI 
0.07 to 1.37, Z = 2.16, I² = 81%) in patients with FEP (all 
<0.05).  Six  cytokines  were  not  significantly  altered  in 
the  FEP  population  when  compared  with  control  sub-
jects. Non- significant effect sizes were reported for TNF- α 
(5  studies,  287  patients),  IL- 1β  (4  studies,  218  patients), 
IL- 2 (3 studies, 99 patients), IL- 4 (3 studies, 99 patients) 
IL- 8  (2  studies,  69  patients)  and  IL- 10  (4  studies,  227 
patients).  Forest  plots  are  presented  in  Figure  3,  broken 
down by study and cytokine of interest.

DUNLEAVY et al. 
   
12 

| 

s
i
s
y
l
a
n
 a
-
a
t
e
m
n

i
d
e
d
u
l
c
n

i

t
o
N

S
S
N
A
P

A
S
I
L
E

,
7
 1
-
L
I

,
0
1
 .
-
L
I

,
 6
-
L
I

,
 4
-
L
I

,
 γ
-
N
F
I

,

 α
-
F
N
T

s

m
o
t
p
m
y
S
e
v
i
t
a
g
e
N

t
n
e
m
m
o
C

t
n
e
m
u
r
t
s
n
I

y
g
o
l
o
d
o
h
t
e
M

d
e
s
s
e
s
s
a
s
e
n
i
k
o
t
y
C

d
e
d
u
l
c
n
I

d
e
d
u
l
c
n
I

d
e
d
u
l
c
n
I

d
e
d
u
l
c
n
I

S
S
N
A
P

S
S
N
A
P

S
N
A
S

A
S
I
L
E

A
S
I
L
E

A
S
I
L
E

 β
-
F
G
T

,
7
 2
-
L
I

 6
-
L
I

,
β
 1
-
L
I

2
 1
-
L
I

7
 1
-
L
I

,
 6
-
L
I

,
 γ
-
N
F
I

S
S
N
A
P

y
a
s
s
A
h
c
i
w
d
n
a
S

,
 4
-
L
I

,
 2
-
L
I

,
β
 1
-
L
I

,

α
 1
-
L
I

,
 γ
-
N
F
I

,

 α
-
F
N
T

s
i
s
y
l
a
n
 a
-
a
t
e
m
n

i
d
e
d
u
l
c
n

i

t
o
N

S
S
N
A
P

y
a
s
s
a
o
n
u
m
m

I

,
 4
-
L
I

,
 2
-
L
I

,
β
 1
-
L
I

,
 γ
-
N
F
I

,
 β
-
F
N
T

,

 α
-
F
N
T

2
 1
-
L
I

,
0
 1
-
L
I

,
 8
-
L
I

,
 6
-
L
I

,
 5
-
L
I

d
e
d
u
l
c
n
I

S
S
N
A
P

y
a
s
s
a
o
n
u
m
m

I

-
L
I

,
β
 1
-
L
I

,
 γ
-
N
F
I

,
2
R
/
1
 R
-
F
N
T
s

,

 α
-
F
N
T

d
e
d
u
l
c
n
I

S
S
N
A
P

y
a
s
s
A
x
e
l
p
i
t
l
u
M

0
 1
-
L
I

,
 8
-
L
I

,
 6
-
L
I

β
 1
-
L
I

s
i
s
y
l
a
n
 a
-
a
t
e
m
n

i
d
e
d
u
l
c
n

i

t
o
N

S
N
A
S

,

S
S
N
A
P

s
i
s
y
l
a
n
 a
-
a
t
e
m
n

i
d
e
d
u
l
c
n

i

t
o
N

S
S
N
A
P

A
S
I
L
E

A
S
I
L
E

,
5
 1
-
L
I

,
3
 1
-
L
I

,
2
 1
-
L
I

,
0
 1
-
L
I

,
 8
-
L
I

,
 7
-
L
I

,
 6
-
L
I

,
 5
-
L
I

,
 4
-
L
I

,
r
 2
-
L
I
s

,
 2
-
L
I

,

A
R
1

 β
-
F
G
T

,
7
 1
-
L
I

,
0
 1
-
L
I

,
 6
-
L
I

,
 2
-
L
I

F
S
 C
M
G

-

,
7
 1
-
L
I

 2
-
L
I

,
β
 1
-
L
I

,

 α
-
F
N
T

d
e
d
u
l
c
n
I

S
S
N
A
P

y
r
t
e
m
o
t
y
C
w
o
l
F

,
0
 1
-
L
I

,
 6
-
L
I

,
 4
-
L
I

,
 2
-
L
I

,
 γ
-
N
F
I

,

 α
-
F
N
T

s
i
s
y
l
a
n
 a
-
a
t
e
m
n

i
d
e
d
u
l
c
n

i

t
o
N

s
i
s
y
l
a
n
 a
-
a
t
e
m
n

i
d
e
d
u
l
c
n

i

t
o
N

d
e
d
u
l
c
n
I

S
S
N
A
P

S
S
N
A
P

S
S
N
A
P

d
e
d
u
l
c
n
I

d
e
d
u
l
c
n
I

S
N
A
S

,

S
S
N
A
P

S
S
N
A
P

y
a
r
r
A
d
a
e
B

A
S
I
L
E

A
S
I
L
E

A
S
I
L
E

A
S
I
L
E

A
S
I
L
E

7
 1
-
L
I

8
 1
-
L
I

0
 1
-
L
I

 3
-
L
I

β
 1
-
L
I

,

 α
-
F
N
T

 α
-
F
N
T

5
3
1

y
h
t
l
a
e
H

l
o
r
t
n
o
c

g
u
r
D

e
v
ï
a
N

w
e
i
v
e
r
n

i
d
e
d
u
l
c
n

i

s
e
i
d
u
t
S

1

E
L
B
A
T

)
n
(

6
3

8
2

0
6

0
6

7
3

0
3

3
2

2
2

8
3

9
3

6
2

8
7

2
6

3
4

1
6

)
n
(
P
E
F

y
t
i
l
a
n
o
i
t
a
N

r
o
h
t
u
A

8
8

6
5

3
8

9
6

8
3

8
2

5
2

1
3

4
5

9
3

0
3

8
7

8
2
1

5
5

9
6

9
1
1

a
i
b
r
e
S

2
1
0
2
,
.
l
a
t
e
n
n
a
c
v
o
r
o
B

i

n
i
a
p
S

8
0
0
2
,
.
l
a
t
e
o
r
r
o
c
a
 F
-
o
p
s
e
r
C

i

a
n
h
C

i

a
n
h
C

a
i
n
o
t
s
E

l
i
z
a
r
B

e
c
e
e
r
G

4
1
0
2
,
.
l
a
t
e
g
n
D

i

0
2
0
2
,
.
l
a
t
e

i
a
D

5
1
0
2
,
.
l
a
t
e
g
n
i
r
a
H

7
1
0
2
,
.
l
a
t
e

s
a
k
i
n
a
r
a
K

8
1
0
2
,
.
l
a
t
e
m
i
u
q
a
o
J

l
i
z
a
r
B

9
1
0
2
,
.
l
a
t
e
o
t
o
N

e
c
e
e
r
G

y
e
k
r
u
T

y
l
a
t
I

i

a
n
h
C

i

a
n
h
C

i

a
n
h
C

i

a
n
h
C

i

a
n
h
C

5
1
0
2
,
.
l
a
t
e

s
i
k
i
r
t
e
P

6
1
0
2
,
.
l
a
t
e
k
e
s
m
i
S

4
1
0
2
,
.
l
a
t
e

e
c
s
e
P

2
1
0
2
,
.
l
a
t
e
u
i
X

4
1
0
2
,
.
l
a
t
e
u
i
X

6
1
0
2
,
.
l
a
t
e
g
n
a
Y

8
1
0
2
,
.
l
a
t
e
u
h
Z

0
2
0
2
,
.
l
a
t
e
u
h
Z

DUNLEAVY et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
|  13

F I G U R E   3  Forest plots displaying 
the standardised mean difference between 
first- episode psychosis(FEP) and control 
for each cytokine. Tests for heterogeneity 
in effect size for each cytokine, as well as 
overall effect size given for each cytokine. 
Also plotted graphically per cytokine, with 
the box size relating to the weight of each 
study, position relating to the difference in 
FEP vs. control, and the emanating lines 
relating to the 95% confidence intervals. 
The diamond represents the overall effect 
size

DUNLEAVY et al. 
   
14 

| 

3.2 

|  Meta- regression analysis

Meta- regression analyses were conducted to assess the ef-
fect of various clinical and sociodemographic factors that 
may  influence  the  significant  changes  in  cytokine  con-
centration  exhibited  in  the  current  meta- analysis.  Due 
to  insufficient  data,  meta- regression  analysis  could  only 
be  conducted  for  potential  moderators  of  IFN- γ  and  IL- 
6, and not IL- 12 or IL- 17. Across the four studies assess-
ing  IFN- γ,  a  significant  association  between  Body  Mass 
Index (BMI) and IFN- γ was found (Z = 1.98, p = 0.048). 
Specifically, as BMI increased in FEP populations, IFN- γ 
also  increased.  Furthermore,  a  significant  association 
between  IFN- γ  and  percentage  male  sex  was  reported 
(Z  =  2.18,  p  =  0.029).  Within  the  six  studies  that  meas-
ured IL- 6, meta- regression analyses revealed a significant 
association between IL- 6 and BMI (Z = 2.89, p < 0.01) and 
IL- 6 and percentage male sex (Z = 3.07, p = <0.01). For 
both cytokines, no significant associations were reported 
for age (p = >0.05), and there were no enough data made 
available by included studies to assess the effects of smok-
ing on cytokine concentration.

Meta- regressions  were  also  conducted  to  assess  the 
effects  of  psychopathology  on  the  meta- analysis  results. 
No significant associations were found for positive symp-
toms, negative symptoms or general psychopathology (all 
p = >0.05).

|  Cytokine and negative 

3.3 
symptom analysis

Due to the lack of available data, extensive analysis of the 
relationship  between  cytokine  concentrations  and  indi-
vidual  negative  symptom  items  could  not  be  performed. 
Therefore, a narrative review was conducted to assess the 
relationship between cytokine concentration and severity 
of  negative  symptoms.  Significant  correlations  between 
the PANSS Negative sub- score and change in inflamma-
tory  markers  were  reported  seven  times,  in  six  different 
studies, with reference to six different cytokines. An over-
view of these findings is presented in Table 2. Moderate 
correlation  strengths  were  reported  for  IL- 6  (r  =  0.48), 
IL- 2 (r = 0.409), TNF- α (r = 0.37) and the PANSS Negative 
sub- score. Furthermore, Dai et al.44 reported a significant 
and positive β- coefficient for the relationship between IL- 
1β and the PANSS Negative sub- score (β = 0.486), which 
suggests that an increase in IL- 1β caused an increase in the 
PANSS Negative subscale. In terms of anti- inflammatory 
cytokines, a strong positive correlation between IL- 4 and 
the PANSS Negative sub- score were reported (r = 0.67).

Furthermore, two correlations were reported between 
IL- 10  and  the  PANSS  Negative  sub- score,  including  a 

strong negative correlation (r = −0.65) reported by Simsek 
et  al.,46  and  a  weak- to- moderate  negative  correlation 
(r  =  −0.195)  reported  by  Xiu  et  al.43  IL- 10  was  reported 
as correlated with the PANSS Negative subscale in 50% of 
studies measuring this cytokine. No other significant re-
lationships were reported (p < 0.05). IL- 10 was reported 
as correlated with the PANSS Negative subscale in 50% of 
studies measuring this cytokine.

4 

|  DISCUSSIO N

The  relationship  between  inflammatory  biomarkers  and 
negative  symptom  severity  in  antipsychotic  naïve  FEP 
populations is an area of research interest as it may offer 
further  insight  into  FEP  aetiology.  Previous  literature 
has  identified  alterations  in  cytokine  concentration  in 
FEP and SCZ populations,17,25,50– 52 which is supported in 
this  meta- analysis.  The  findings  presented  demonstrate 
that  IFN- γ,  IL- 6,  IL- 12  and  IL- 17  are  all  significantly  in-
creased  in  medication  naïve  FEP.  This  is  indicative  of  a 
perturbed inflammatory response in the very early stages 
of  psychosis.  We  add  additional  evidence  here,  bringing 
further contemporary studies that suggest specific proin-
flammatory cytokine aberrations are evident in early SCZ 
pathology,  unconfounded  by  antipsychotic  medication 
and  chronicity  of  disease.  Although  sufficient  raw  data 
to allow in- depth analysis were not made available from 
many studies, significant relationships between negative 
symptoms  and  IL- 1β,  IL- 2,  IL- 4,  IL- 6  IL- 10  and  TNF- α 
were identified from cohort data provided in each study 
independently. This review further supports the hypoth-
esis of a dysregulated immune system as a key component 
of  SCZ  pathology,  and  the  current  analysis  implicates 
immune  perturbations  within  the  very  earliest  stages  of 
psychosis.

Aberrations  in  the  peripheral  concentration  of  cy-
tokines  can  manifest  in,  and  indicate  a  state  of,  chronic 
neuroinflammation.53  This  has  been  described  in  the 
‘vulnerability- stress- inflammation’  model  as  fundamen-
tal  for  SCZ  development.54  It  is  suggested  that  stressor- 
induced  proinflammatory  cytokine  elevations  that  occur 
in early life, for example elevations in IFN-  γ, can cause 
proliferation  of  immune  cells  within  the  brain  and  cen-
tral  nervous  system  (CNS)  and  exacerbated  proinflam-
matory cytokine release. Chronic inflammation can then 
perturb  neurotransmitter  systems,  cause  neurodegener-
ation  and  lead  to  eventual  psychotic  symptom  presenta-
tion.55,56  Cytokines  do  not  work  independently  and  may 
operate  through  an  inflammatory  network  to  recipro-
cally  upregulate  other  cyto-   and  chemokines  and  exac-
erbate  inflammation.  This  may  explain  why  cytokines 
appear to be upregulated simultaneously in patterns and 

DUNLEAVY et al. 
 
T A B L E   2  Cytokine concentration in antipsychotic- naïve FEP per study, PANSS Negative sub- score and relationship between cytokine 
and negative symptoms

|  15

Cytokine/
Negative symptom 
relationship

NS

NS

NS

Cytokine

Author

Cytokine
(Pg/ml, 
mean)

PANSS 
negative
(mean)

Analytical 
method

IL- 1β

Haring et al., 2015

1.35

22.97

Pearson 

correlation

Findings

r = 0.232

Joaquim et al., 2018

0.28

18.00

Pearson 

Not stated

Zhu et al., 2018

Dai et al., 2020

1.70

69.48

25.60

22.16

correlation

Partial correlation

Not stated

Multivariate 
regression

β = 0.486

*Positive

IFN- γ

Ding et al., 2014

509.73

18.23

Pearson 

r = 0.074

Haring et al., 2015

Simsek et al., 2016

Noto et al., 2019

0.35

2.90

7.03

correlation

22.97

Pearson 

r = 0.162

correlation

26.30

Pearson 

r = 0.30

correlation

20.59

Multiple 

Not stated

NS

NS

NS

NS

IL- 2

Haring et al., 2015

3.00

22.97

regression

Pearson 

correlation

r = 0.409

*Positive

Simsek et al., 2016

20.00

26.30

Pearson 

r = −0.12

correlation

Noto et al., 2019

IL- 4

Haring et al., 2015

2.34

1.73

20.59

Multiple 

Not stated

regression

22.97

Pearson 

r = 0.073

NS

NS

NS

Simsek et al., 2016

30.5

26.30

correlation

Pearson 

correlation

r = 0.67

*Positive

Noto et al., 2019

13.75

20.59

Multiple 

Not stated

regression

IL- 6

Ding et al., 2014

14.75

18.23

Pearson 

r = 0.168

Haring et al., 2015

Simsek et al., 2016

Noto et al., 2019

Dai et al., 2020

IL- 8

Haring et al., 2015

Noto et al., 2019

1.35

4.30

3.08

5.37

5.92

9.78

NS

NS

NS

NS

correlation

22.97

Pearson 

r = 0.227

correlation

26.30

Pearson 

r = −0.57

20.59

22.16

correlation

Multiple 

regression

Multivariate 
regression

22.97

Pearson 

r = 0.04

correlation

20.59

Multiple 

Not stated

regression

r = 0.48

*Positive

β = 0.130

NS

NS

NS

(Continues)

DUNLEAVY et al. 
   
16 

| 

T A B L E   2 

(Continued)

Cytokine

Author

Cytokine
(Pg/ml, 
mean)

PANSS 
negative
(mean)

Analytical 
method

IL- 10

Xiu et al., 2014

39.20

18.90

Pearson 

correlation

Findings

r = −0.195

Cytokine/
Negative symptom 
relationship

*Negative

Haring et al., 2015

0.62

22.97

Pearson 

r = 0.097

NS

Simsek et al., 2016

5.10

26.30

correlation

Pearson 

correlation

r = −0.65

*Negative

Noto et al., 2019

7.20

20.59

Multiple 

Not stated

regression

IL- 12

Crespo- Facorro 
et al., 2018

50.2

10.11

Pearson 

Not stated

correlation

Noto et al., 2019

28.74

20.59

Multiple 

Not stated

regression

IL- 17

Ding et al., 2014

17.69

18.23

Pearson 

r = 0.204

correlation

Simsek et al., 2016

7.60

26.30

Pearson 

r = 0.23

correlation

Noto et al., 2019

12.33

20.59

Multiple 

Not stated

TNF- α

Haring et al., 2015

Simsek et al., 2016

Zhu et al., 2018

Noto et al., 2019

Zhu et al., 2020

2.05

9.20

8.20

4.12

2.21

regression

22.97

Pearson 

r = 0.034

correlation

26.30

Pearson 

r = −0.46

25.60

20.59

26.89

correlation

Partial correlation

Not stated

Not stated

Multiple 

regression

Multiple 

regression

r = 0.37

*Positive

NS

NS

NS

NS

NS

NS

NS

NS

NS

NS

Studies in bold, and marked with an asterisk (*) report a significant correlation between variables (p < 0.05). ‘NS’ indicates no significant correlation between 
variables.

not  in  isolation,  as  reported  in  the  current  review  and 
elsewhere.26

Several  studies  included  in  the  review  reported  a  sig-
nificant  relationship  between  cytokines  and  negative 
symptoms  (displayed  in Table  2).  Proinflammatory  cyto-
kine concentrations of IL- 1β, IL- 2, IL- 6 and TNF- α were 
all  significantly  related  to  the  PANSS  negative  subscale, 
whereby  an  increase  in  proinflammatory  cytokine  con-
centration  was  related  to  an  increase  in  the  severity  of 
negative  symptoms. These  findings  have  been  replicated 
across the SCZ spectrum, occurring as early as at- risk of 
psychosis,21,57 through FEP,44,48 and into chronic SCZ.23 It 
is suggested that proinflammatory cytokines that induce 
a ‘neuroinflammatory state’ within the CNS, may lead to 
brain  volume  reductions  in  areas  that  are  important  for 
negative  symptom  emergence,  including  prefrontal  and 
hippocampal  regions  of  the  brain.15,58  Proinflammatory 
cytokines can perturb neurotransmitter pathways to alter 

brain signalling, and negative symptoms may be induced 
in this way. Evidence suggests that proinflammatory cyto-
kines may be responsible for the induction of N- Methyl- 
D- Aspartate  receptor  antagonist  kynurenic  acid,  which 
can  cause  dysfunction  in  glutamatergic  signalling  and 
subsequent motivational and reward processing deficits.15 
Similarly,  anti- inflammatory  cytokine  alterations  have 
been reported to be related to the emergence of negative 
symptoms across all stages of schizophrenia, whereby typ-
ically  lower  anti- inflammatory  cytokine  concentrations 
are associated with increased negative symptom severity.43 
Overall, this may represent a more generalised imbalance 
of the T- helper system, causing a polarisation to a chronic 
proinflammatory state that is insufficiently quenched by 
anti- inflammatory  responses.24  Therefore,  chronic  low- 
grade  inflammation  that  is  present  in  psychosis,  could 
cause eventual presentation of symptoms via perturbation 
in neurotransmission.

DUNLEAVY et al. 
 
The relationship between specific cytokines and nega-
tive symptom severity in FEP show significant heteroge-
neity, despite the overall disruption of immune function. 
This  could  be  apparent  for  various  reasons.  First,  FEP 
and  eventual  SCZ  is  polygenic  by  nature,  meaning  that 
individuals  with  psychosis  may  possess  varied  profiles 
of  susceptibility  genes  implicated  with  SCZ  pathology.59 
For example some FEP populations may not have certain 
immune- related polymorphisms that confer increases the 
production  of  a  specific  cytokine,  and  therefore  patients 
may display normal plasma protein concentration. Given 
that  the  included  studies  did  not  genetically  screen  par-
ticipants, this could be responsible for a lack of consistent 
correlations of a given cytokine with negative symptoms. 
Furthermore,  the  extent  of  the  interaction  between  cy-
tokines  within  signalling  cascades  in  ongoing  immune 
responses is not known, and plasma concentrations may 
vary  between  individuals.  Heterogeneity  may  also  arise 
because  of  confounding  environmental  factors  includ-
ing smoking status, diet and stress exposure, which may 
obscure cytokine concentrations and mask genuine rela-
tionships  between  cytokines  and  symptoms.  Due  to  in-
sufficient  data  and  lack  of  studies  investigating  certain 
cytokines,  meta- regression  analysis  could  only  be  con-
ducted  for  potential  moderators  of  IFN- γ  and  IL- 6,  and 
not IL- 12 or IL- 17. The relationship between IFN- γ or IL- 6 
and negative symptoms was significantly affected by BMI 
and  in  studies  with  a  higher  proportion  of  male  partici-
pants. Evidence elsewhere suggests that tobacco smoking 
is common amongst the FEP population and may interact 
with immune functioning peripherally,60,61 however, dis-
crepancies in data reporting meant that this could not be 
investigated on a larger scale. This highlights a key consid-
eration  when  designing  studies  looking  at  cytokine  pro-
files in FEP and SCZ population, in addition to the need 
for  better  demographic  reports  in  papers.  Insufficient 
available data may be responsible for the lack of an over-
all relationship of a specific cytokine with negative symp-
toms, as meta- regressions typically require high numbers 
of  studies  to  determine  genuine  relationships.  Recently, 
attempts  to  resolve  some  of  these  issues  surrounding 
heterogeneity  have  utilised  immunophenotyping  and 
genetically stratifying patient cohorts into ‘high’ or ‘low’ 
inflammation.62,63 Stratification of patients into high and 
low inflammatory subtypes may better reveal the relation-
ship  between  inflammation  and  negative  symptoms,  as 
opposed to individual cytokine concentrations which vary 
considerably between individuals. Better characterisation 
of  FEP  subgroups  into  ‘high’  or  ‘low’  inflammation,  as 
well as subgroups of cytokines that are typically upregu-
lated together will reveal more about the relationship be-
tween cytokines and symptomology.

|  17

More definitive criteria for FEP diagnosis are required, 
as  circulating  cytokine  concentration  in  FEP  and  SCZ 
appears to be affected by the duration of illness, antipsy-
chotic  medication,  and  associated  comorbidities.  This 
systematic review utilised the operationalised definitions 
described  by  Breitborde  et  al.,  in  order  to  classify  an  in-
dividual as within a period of ‘first episode of psychosis’, 
accounting for the entire ‘critical period’ of deterioration 
that  defines  FEP.64  Furthermore,  this  systematic  review 
ensured absolute drug naivety in included studies, to pro-
vide an accurate and minimally confounded overview of 
the relationship between cytokines and primary negative 
symptomology within FEP.

Although  the  current  meta- analysis  was  largely  in 
agreement  with  other  studies,  there  were  some  key  dif-
ferences,  for  example  the  changes  in  IL- 1β  and  TNF- α 
reported herein were not significant. This may in part be 
explained  by  the  specific  definition  of  FEP  used  in  this 
study  to  accurately  represent  the  early  stages  of  disease. 
Our approach may offer a more accurate representation of 
the early psychosis spectrum, which includes all patients 
with FEP. This is key, as the ‘critical period’ of deteriora-
tion in FEP can occur for up to five years and therefore it 
is logical to assess cytokines over this entire timeframe.65 
This  may  result  in  differences  with  reviews  elsewhere 
based  upon  FEP  definitions,  as  some  cytokines  that  are 
identified as a ‘state’ cytokines which are increased upon 
acute  exacerbations  of  disease,  may  have  somewhat 
normalised  in  concentration  if  a  longer  time  period  has 
elapsed since their first psychotic episode.17 Alternatively, 
the discrepancy in findings between studies included and 
elsewhere  may  be  a  consequence  of  methodological  dif-
ferences across studies, including researcher competence, 
experimental  error  and  protocol  variations.66 Within  the 
current review, several different cytokine assay platforms 
are  used  between  studies,  varying  from  single  cytokine 
measures  to  multiplex  systems,  which  can  significantly 
impact  assay  sensitivity. These  factors  make  comparison 
of cytokine concentration between studies difficult.

The  current  systematic  review  suggests  that  several 
cytokines  are  elevated  in  FEP,  providing  further  evi-
dence  for  a  central  role  of  perturbed  inflammation  in 
early SCZ pathology. The review highlighted several rela-
tionships between different cytokines and the severity of 
negative  symptomology,  whereby  elevated  proinflamma-
tory  immune  activation  and  inability  to  mount  an  anti- 
inflammatory  response  appear  to  confer  worse  negative 
symptom  presentation.  Future  research  should  focus  on 
identifying the cytokines most relevant to negative symp-
tomology, investigate cytokine concentration fluctuations 
and symptom profiles over a longitudinal period, and con-
sider  phenotyping  of  peripheral  immune  cells  to  better 

DUNLEAVY et al. 
   
18 

| 

define immune dysregulation profiles in psychosis. It may 
be that longer periods of persistent inflammation are the 
driving factors for negative behaviours, rather than the ef-
fects of a given cytokine, the majority of which possess a 
multitude of pleiotropic effects. This may assist in identify-
ing individuals experiencing primary negative symptoms, 
for the delivery of anti- inflammatory medication to better 
manage symptomology and improve outcomes in FEP.

CONFLICT  OF INTEREST
The  authors  declare  that  the  research  was  conducted 
in the absence of any commercial or financial relation-
ships  that  could  be  construed  as  a  potential  conflict  of 
interest.

PEE R  RE VIEW
The  peer  review  history  for  this  article  is  available  at 
https://publo ns.com/publo n/10.1111/acps.13416.

DATA  AVAI LABILITY STAT EM E NT
This data will be made available and provided in full on 
suitable request.

ORCID
Connor Dunleavy 
org/0000-0003-2340-9012 

 https://orcid.

R E F E R E N C E S
  1.  Weinberger  DR.  Implications  of  normal  brain  development 
for  the  pathogenesis  of  schizophrenia.  Arch  Gen  Psychiatry. 
1987;44(7):660- 669.

  2.  James SL, Abate D, Abate KH, et al. Global, regional, and na-
tional  incidence,  prevalence,  and  years  lived  with  disability 
for 354 diseases and injuries for 195 countries and territories, 
1990– 2017:  a  systematic  analysis  for  the  Global  Burden  of 
Disease Study 2017. Lancet. 2018;392(10159):1789- 1858.
  3.  Van  Os  J,  Kenis  G,  Rutten  BP.  The  environment  and  schizo-

phrenia. Nature. 2010;468(7321):203- 212.

  4.  Tsuang  M.  Schizophrenia:  genes  and  environment.  Biol 

Psychiat. 2000;47(3):210- 220.

  5.  NCCMH.  Psychosis  and  Schizophrenia  in  Adults:  Treatment 
and  Management.  National  Institute  for  Health  and  Care 
Excellence; 2014. Updated edition 2014.

  6.  Addington  D,  Jean  Addington  M,  Patten  S.  Relapse  rates  in 
an  early  psychosis  treatment  service.  Acta  Psychiatr  Scand. 
2007;115(2):126- 131.

  7.  Eack  SM,  Newhill  CE.  Psychiatric  symptoms  and  quality 
of  life  in  schizophrenia:  a  meta- analysis.  Schizophr  Bull. 
2007;33(5):1225- 1237.

  8.  Robertson  BR,  Prestia  D,  Twamley  EW,  Patterson  TL,  Bowie 
CR, Harvey PD. Social competence versus negative symptoms 
as predictors of real world social functioning in schizophrenia. 
Schizophr Res. 2014;160(1– 3):136- 141.

  9.  Andreasen  NC.  Negative  symptoms  in  schizophrenia:  defini-

tion and reliability. Arch Gen Psychiatry. 1982;39(7):784- 788.

 10.  American  Psychiatric  Association.  Diagnostic  and  Statistical 
Manual of Mental Disorders, 5th edition. American Psychiatric 
Association; 2013; 21.

 11.  Foussias  G,  Remington  G.  Negative  symptoms  in  schizo-
phrenia:  avolition  and  Occam's  razor.  Schizophr  Bull. 
2010;36(2):359- 369.

 12.  Kirschner  M,  Aleman  A,  Kaiser  S.  Secondary  negative  symp-
toms— a  review  of  mechanisms,  assessment  and  treatment. 
Schizophr Res. 2017;186:29- 38.

 13.  Austin SF, Mors O, Budtz- Jørgensen E, et al. Long- term trajec-
tories  of  positive  and  negative  symptoms  in  first  episode  psy-
chosis: a 10 year follow- up study in the OPUS cohort. Schizophr 
Res. 2015;168(1– 2):84- 91.

 14.  Malla  AK,  Takhar  JJ,  Norman  RM,  et  al.  Negative  symptoms 
in first episode non- affective psychosis. Acta Psychiatr Scand. 
2002;105(6):431- 439.

 15.  Goldsmith  DR,  Rapaport  MH.  Inflammation  and  negative 
symptoms of schizophrenia: implications for reward processing 
and motivational deficits. Front Psychiatry. 2020;11:46.

 16.  Mas S, Gassó P, Fernandez de Bobadilla R, Arnaiz JA, Bernardo 
M,  Lafuente  A.  Secondary  nonmotor  negative  symptoms  in 
healthy volunteers after single doses of haloperidol and risper-
idone: a double- blind, crossover, placebo- controlled trial. Hum 
Psychopharmacol. 2013;28(6):586- 593.

 17.  Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta- 
analysis of cytokine alterations in schizophrenia: clinical status 
and antipsychotic effects. Biol Psychiat. 2011;70(7):663- 671.
 18.  Bloomfield PS, Selvaraj S, Veronese M, et al. Microglial activity 
in people at ultra high risk of psychosis and in schizophrenia: 
an  [11C]  PBR28  PET  brain  imaging  study.  Am  J  Psychiatry. 
2016;173(1):44- 52.

 19.  Réus  GZ,  Fries  GR,  Stertz  L,  et  al.  The  role  of  inflammation 
and microglial activation in the pathophysiology of psychiatric 
disorders. Neuroscience. 2015;300:141- 154.

 20.  Garcia- Rizo  C,  Fernandez- Egea  E,  Oliveira  C,  Justicia 
A,  Bernardo  M,  Kirkpatrick  B.  Inflammatory  markers 
in  antipsychotic- naïve  patients  with  nonaffective  psy-
chosis  and  deficit  vs.  nondeficit  features.  Psychiatry  Res. 
2012;198(2):212- 215.

 21.  Goldsmith DR, Haroon E, Miller AH, et al. Association of base-
line  inflammatory  markers  and  the  development  of  negative 
symptoms  in  individuals  at  clinical  high  risk  for  psychosis. 
Brain Behav Immun. 2019;76:268- 274.

 22.  Perry BI, Zammit S, Jones PB, Khandaker GM. Childhood in-
flammatory markers and risks for psychosis and depression at 
age  24:  examination of  temporality  and  specificity  of  associa-
tion in a population- based prospective birth cohort. Schizophr 
Res. 2021;230:69- 76.

 23.  Goldsmith DR, Haroon E, Miller AH, Strauss GP, Buckley PF, 
Miller BJ. TNF- α and IL- 6 are associated with the deficit syn-
drome and negative symptoms in patients with chronic schizo-
phrenia. Schizophr Res. 2018;199:281- 284.

 24.  Kim Y- K, Myint A- M, Lee B- H, et al. Th1, Th2 and Th3 cytokine 
alteration in schizophrenia. Prog Neuropsychopharmacol Biol 
Psychiatry. 2004;28(7):1129- 1134.

 25.  Upthegrove  R,  Manzanares- Teson  N,  Barnes  NM.  Cytokine 
function in medication- naive first episode psychosis: a system-
atic  review  and  meta- analysis.  Schizophr  Res.  2014;155(1– 3): 
101- 108.

DUNLEAVY et al. 
 
 26.  Goldsmith D, Rapaport M, Miller BJ. A meta- analysis of blood 
cytokine network alterations in psychiatric patients: compari-
sons between schizophrenia, bipolar disorder and depression. 
Mol Psychiatry. 2016;21(12):1696- 1709.

 27.  Momtazmanesh S, Zare- Shahabadi A, Rezaei N. Cytokine alter-
ations  in  schizophrenia:  an  updated  review.  Front  Psychiatry. 
2019;10:892.

 43.  Xiu  MH,  Yang  GG,  Tan  YL,  et  al.  Decreased  interleukin- 10 
serum  levels  in  first- episode  drug- naïve  schizophrenia:  rela-
tionship to psychopathology. Schizophr Res. 2014;156(1):9- 14.

 44.  Dai N, Jie H, Duan Y, et al. Different serum protein factor levels 
in  first- episode  drug- naïve  patients  with  schizophrenia  char-
acterized  by  positive  and  negative  symptoms.  Psychiatry  Clin 
Neurosci. 2020;74(9):472- 479.

 28.  Zhu F, Zhang L, Liu F, et al. Altered serum tumor necrosis fac-
tor and interleukin- 1β in first- episode drug- naive and chronic 
schizophrenia. Front Neurosci. 2018;12:296.

 45.  Joaquim HP, Costa AC, Gattaz WF, Talib LL. Kynurenine is cor-
related with IL- 1β in plasma of schizophrenia patients. J Neural 
Transm. 2018;125(5):869- 873.

|  19

 29.  Zhu S, Zhao L, Fan Y, et al. Interaction between TNF- α and ox-
idative stress status in first- episode drug- naïve schizophrenia. 
Psychoneuroendocrinology. 2020;114:104595.

 30.  Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred 
reporting items for systematic reviews and meta- analyses: the 
PRISMA statement. PLoS Med. 2009;6(7):e1000097.

 31.  Kay  SR,  Fiszbein  A,  Opler  LA.  The  positive  and  negative 
syndrome  scale  (PANSS)  for  schizophrenia.  Schizophr  Bull. 
1987;13(2):261- 276.

 32.  Deeks JJ, Higgins JP, Altman DG, Group CSM. Analysing data 
and  undertaking  meta- analyses.  In:  Higgins  JPT,  Thomas  J, 
Chandler  J,  et  al.  (eds).  Cochrane  Handbook  for  Systematic 
Reviews of Interventions. 2nd ed. Chichester, UK: John Wiley 
& Sons; 2019:241- 284.

 33.  Van Erp TG, Preda A, Nguyen D, et al. Converting positive and 
negative  symptom  scores  between  PANSS  and  SAPS/SANS. 
Schizophr Res. 2014;152(1):289- 294.

 34.  DerSimonian  R,  Laird  N.  Meta- analysis  in  clinical  trials. 

Control Clin Trials. 1986;7(3):177- 188.

 35.  Higgins JP, Li T, Deeks JJ. Choosing effect measures and com-
puting estimates of effect. In: Higgins JPT, Thomas J, Chandler 
J,  et  al.  (eds).  Cochrane  Handbook  for  Systematic  Reviews  of 
Interventions.  2nd  ed.  Chichester,  UK:  John  Wiley  &  Sons; 
2019:143- 176.

 36.  Borovcanin M, Jovanovic I, Radosavljevic G, et al. Antipsychotics 
can  modulate  the  cytokine  profile  in  schizophrenia:  attenu-
ation  of  the  type- 2  inflammatory  response.  Schizophr  Res. 
2013;147(1):103- 109.

 37.  Borovcanin  M,  Jovanovic  I,  Dejanovic  SD,  Radosavljevic 
G,  Arsenijevic  N,  Lukic  ML.  Increase  systemic  levels  of 
IL- 23  as  a  possible  constitutive  marker  in  schizophrenia. 
Psychoneuroendocrinology. 2015;56:143- 147.

 38.  Borovcanin  MM,  Janicijevic  SM,  Jovanovic  IP,  Gajovic  N, 
Arsenijevic NN, Lukic ML. IL- 33/ST2 pathway and galectin- 3 
as  a  new  analytes  in  pathogenesis  and  cardiometabolic  risk 
evaluation in psychosis. Front Psychiatry. 2018;9:271.

 39.  Xiu M- H, Wang D, Chen S, et al. Interleukin- 3, symptoms and 
cognitive deficits in first- episode drug- naïve and chronic medi-
cated schizophrenia. Psychiatry Res. 2018;263:147- 153.

 40.  Zhang XY, Tang W, Xiu MH, et al. Interleukin 18 and cognitive 
impairment in first episode and drug naïve schizophrenia ver-
sus healthy controls. Brain Behav Immun. 2013;32:105- 111.
 41.  Noto C, Ota VK, Santoro ML, et al. Effects of depression on the 
cytokine profile in drug naive first- episode psychosis. Schizophr 
Res. 2015;164(1– 3):53- 58.

 42.  Crespo- Facorro  B,  Carrasco- Marin  E,  Perez- Iglesias  R,  et  al. 
Interleukin- 12 plasma levels in drug- naive patients with a first 
episode of psychosis: effects of antipsychotic drugs. Psychiatry 
Res. 2008;158(2):206- 216. doi:10.1016/j.psych res.2006.08.005

 46.  Şimşek Ş, Yıldırım V, Çim A, Kaya S. Serum IL- 4 and IL- 10 lev-
els correlate with the symptoms of the drug- naive adolescents 
with  first  episode,  early  onset  schizophrenia.  J  Child  Adolesc 
Psychopharmacol. 2016;26(8):721- 726.

 47.  Ding M, Song X, Zhao J, et al. Activation of Th17 cells in drug 
naïve, first episode schizophrenia. Prog Neuropsychopharmacol 
Biol Psychiatry. 2014;51:78- 82.

 48.  Noto  MN,  Maes  M,  Nunes  SOV,  et  al.  Activation  of  the 
immune- inflammatory response system and the compensatory 
immune- regulatory system in antipsychotic naive first episode 
psychosis. Eur Neuropsychopharmacol. 2019;29(3):416- 431.
 49.  Haring  L,  Koido  K,  Vasar  V,  et  al.  Antipsychotic  treatment 
reduces  psychotic  symptoms  and  markers  of  low- grade  in-
flammation  in  first  episode  psychosis  patients,  but  increases 
their  body  mass  index.  Schizophr  Res.  2015;169(1– 3):22- 29. 
doi:10.1016/j.schres.2015.08.027

 50.  Fraguas  D,  Díaz- Caneja  CM,  Ayora  M,  et  al.  Oxidative  stress 
and  inflammation  in  first- episode  psychosis:  a  systematic  re-
view and meta- analysis. Schizophr Bull. 2019;45(4):742- 751.
 51.  Pillinger  T,  Osimo  EF,  Brugger  S,  Mondelli  V,  McCutcheon 
RA, Howes OD. A meta- analysis of immune parameters, vari-
ability,  and  assessment  of  modal  distribution  in  psychosis 
and test of the immune subgroup hypothesis. Schizophr Bull. 
2019;45(5):1120- 1133.

 52.  Frydecka D, Krzystek- Korpacka M, Lubeiro A, et al. Profiling 
inflammatory  signatures  of  schizophrenia:  a  cross- sectional 
and meta- analysis study. Brain Behav Immun. 2018;71:28- 36.

 53.  Wang  AK,  Miller  BJ.  Meta- analysis  of  cerebrospinal  fluid  cy-
tokine and tryptophan catabolite alterations in psychiatric pa-
tients:  comparisons  between  schizophrenia,  bipolar  disorder, 
and depression. Schizophr Bull. 2018;44(1):75- 83.

 54.  Müller  N.  Inflammation 

in  schizophrenia:  pathogenetic 
therapeutic  considerations.  Schizophr  Bull. 

aspects  and 
2018;44(5):973- 982.

 55.  Watkins  CC,  Andrews  SR.  Clinical  studies  of  neuroin-
flammatory  mechanisms  in  schizophrenia.  Schizophr  Res. 
2016;176(1):14- 22.

 56.  Monji  A,  Kato T,  Kanba  S.  Cytokines  and  schizophrenia:  mi-
croglia hypothesis of schizophrenia. Psychiatry Clin Neurosci. 
2009;63(3):257- 265.

 57.  Stojanovic A, Martorell L, Montalvo I, et al. Increased serum in-
terleukin- 6 levels in early stages of psychosis: associations with 
at- risk  mental  states  and  the  severity  of  psychotic  symptoms. 
Psychoneuroendocrinology. 2014;41:23- 32.

 58.  Kalmady  SV,  Venkatasubramanian  G,  Shivakumar  V,  et  al. 
Relationship  between  Interleukin- 6  gene  polymorphism  and 
hippocampal  volume 
in  antipsychotic- naive  schizophre-
nia:  evidence  for  differential  susceptibility?  PLoS  One. 
2014;9(5):e96021.

DUNLEAVY et al. 
   
20 

| 

 59.  Ripke S, O'Dushlaine C, Chambert K, et al. Genome- wide as-
sociation analysis identifies 13 new risk loci for schizophrenia. 
Nat Genet. 2013;45(10):1150- 1159.

 60.  De  Leon  J,  Diaz  FJ.  A  meta- analysis  of  worldwide  studies 
demonstrates  an  association  between  schizophrenia  and  to-
bacco smoking behaviors. Schizophr Res. 2005;76(2– 3):135- 157.
 61.  Zhang XY, Cao LY, Song C, et al. Lower serum cytokine levels 
in  smokers  than  nonsmokers  with  chronic  schizophrenia  on 
long- term treatment with antipsychotics. Psychopharmacology. 
2008;201(3):383- 389.

 62.  Kindler  J,  Lim  CK,  Weickert  CS,  et  al.  Dysregulation  of  ky-
nurenine metabolism is related to proinflammatory cytokines, 
attention, and prefrontal cortex volume in schizophrenia. Mol 
Psychiatry. 2020;25(11):2860- 2872.

 63.  Fillman  SG,  Sinclair  D,  Fung  SJ,  Webster  MJ,  Weickert  CS. 
Markers  of  inflammation  and  stress  distinguish  subsets  of 
individuals  with  schizophrenia  and  bipolar  disorder.  Transl 
Psychiat. 2014;4(2):e365.

 64.  Breitborde NJ, Srihari VH, Woods SW. Review of the operational 
definition  for  first- episode  psychosis.  Early  Interv  Psychiatry. 
2009;3(4):259- 265.

 65.  Birchwood  M,  Todd  P,  Jackson  C.  Early  intervention  in 
psychosis:  the  critical  period  hypothesis.  Br  J  Psychiatry. 
1998;172(S33 ):53- 59.

 66.  Leng SX, McElhaney JE, Walston JD, Xie D, Fedarko NS, Kuchel 
GA. ELISA and multiplex technologies for cytokine measure-
ment in inflammation and aging research. J Gerontol A Biol Sci 
Med Sci. 2008;63(8):879- 884.

SUPPORT IN G INFORMAT ION
Additional  supporting  information  may  be  found  in  the 
online version of the article at the publisher’s website.

How to cite this article: Dunleavy C, Elsworthy 
RJ, Upthegrove R, Wood SJ, Aldred S. 
Inflammation in first- episode psychosis: The 
contribution of inflammatory biomarkers to the 
emergence of negative symptoms, a systematic 
review and meta- analysis. Acta Psychiatr Scand. 
2022;146:6– 20. doi:10.1111/acps.13416

DUNLEAVY et al.
